false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Autosom ...
Panel Discussion - Holistic ADPKD Patient-Centered ...
Panel Discussion - Holistic ADPKD Patient-Centered Care
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The session reviewed three challenging cases involving ADPKD diagnosis and management. A 21-year-old woman with a strong family history had enlarged, cyst-filled kidneys and a Mayo imaging class near 1D/1E, indicating risk of rapid progression. Discussion covered lifestyle measures, tolvaptan eligibility, gradual dose titration to improve tolerability, required REMS monitoring, clinical-trial options, and shared decision-making.<br /><br />A 67-year-old man referred for presumed ADPKD had enlarged cystic kidneys, hearing loss, hematuria, and proteinuria. Genetic testing identified a pathogenic COL4A5 variant consistent with X-linked Alport syndrome; two PKD1 variants remained uncertain. The case illustrated that Alport syndrome can cause a cystic kidney phenotype and mimic ADPKD.<br /><br />A woman diagnosed with ADPKD before birth and treated for kidney failure in childhood was found to have two PKHD1 variants, consistent with autosomal recessive polycystic kidney disease. Her PKD1 variant was reclassified as benign, changing her diagnosis and informing reproductive counseling.<br /><br />The discussion emphasized careful family history, appropriate genetic testing and counseling, the limitations of uncertain variants, and using affected relatives’ genetic results when possible. When testing is inconclusive, imaging and follow-up should be individualized.
Asset Caption
Arlene B. Chapman, MD; Meyeon Park, MD, FASN; Ronald D. Perrone, MD, FASN
Keywords
ADPKD
tolvaptan
Mayo imaging class
COL4A5
Alport syndrome
PKHD1
genetic testing
autosomal recessive polycystic kidney disease
REMS monitoring
×
Please select your language
1
English